JUAN SEPULVEDA
Dr Sepúlveda is a neurologist and medical oncologist, Director of the Multidisciplinary Neuro-Oncology Unit of the University Hospital 12 Octubre, Madrid, Spain.
Throughout his career, he has been involved in the design and development of clinical trials in brain tumours, from phase I studies to phase III clinical trials. He has also conducted translational studies that have led to the discovery of new therapeutic targets in gliomas. He is currently a member of the Spanish Neuro-Oncology Group (GEINO), of which he has been President, and is also a member of the EORTC Brain Tumour Group. Dr Sepúlveda has published more than 200 scientific articles, mainly in the field of neuro-oncology.
Throughout his career, he has been involved in the design and development of clinical trials in brain tumours, from phase I studies to phase III clinical trials. He has also conducted translational studies that have led to the discovery of new therapeutic targets in gliomas. He is currently a member of the Spanish Neuro-Oncology Group (GEINO), of which he has been President, and is also a member of the EORTC Brain Tumour Group. Dr Sepúlveda has published more than 200 scientific articles, mainly in the field of neuro-oncology.
Confira a agenda de atividades
23 DE MARÇO | SÁBADO
• Room 1
08:15-10:30
SESSION 3: DIFFUSE GLIOMAS
Cannabinoids in glioma treatment
How should be clinical and cognitive assessment in neurooncology?
Advances in patients specific brain mapping strategies
Is there any role for radiosurgery in recurrent gliomas?
The role of re-resection for recurrent IDHwt gliomas
Neuroplasticity and neuroprotection under the radiation oncologist view
Is dexamethasone still the best friend of neuro oncologist?
Discussion
Moderator: Joab Alves Nicacio Junior (SP)
Moderator: Lucas Alverne Freitas de Albuquerque (CE)
Moderator: Gustavo Matos (DF)
Cannabinoids in glioma treatment
Speaker: Juan Sepulveda (Espanha)
How should be clinical and cognitive assessment in neurooncology?
Speaker: Yvonne Kew (Estados Unidos)
Advances in patients specific brain mapping strategies
Speaker: Shawn Hervey-jumper (Estados Unidos)
Is there any role for radiosurgery in recurrent gliomas?
Speaker: Marcos Duarte de Mattos (SP)
The role of re-resection for recurrent IDHwt gliomas
Speaker: Sujit Prabhu (Estados Unidos)
Neuroplasticity and neuroprotection under the radiation oncologist view
Speaker: Fabio Ynoe de Moraes (Canadá)
Is dexamethasone still the best friend of neuro oncologist?
Speaker: Adrialdo José Santos (SP)
Discussion
12:15-13:15
SIMPÓSIO SATÉLITE SERVIER: NEW FRONTIRES IN LGG TREATMENT (RESTRITO PARA PRESCRITORES)
LGG Clinical case
Navigating Low-Grade Glioma for Neurosurgeons: Key Decision Factors and Clinical Approaches
Translating recent clinical evidence in LGG into clinical practice
Q&A
LGG Clinical case
Speaker: Caroline Chaul (SP)
Navigating Low-Grade Glioma for Neurosurgeons: Key Decision Factors and Clinical Approaches
Speaker: Shawn Hervey-jumper (Estados Unidos)
Translating recent clinical evidence in LGG into clinical practice
Speaker: Juan Sepulveda (Espanha)
Q&A
13:30-15:30
SESSION 4: DIFFUSE GLIOMAS
A Critical Overview of Targeted Therapies for Glioma
Translational research for gliomas: future landscapes and emerging paradigm
The role of CAR T cell therapy in neurooncology
What we do know about non-standard of care treatments for gliomas: cannabis, antidepressants, metformin and others
Bevacizumab, is there still a role for antiangiogenics in glioblastoma?
The optimal timing of palliative care in glioma patients
How feasible is surgery in the motor area?
Discussion
Moderator: ícaro Thiago de Carvalho (SP)
A Critical Overview of Targeted Therapies for Glioma
Speaker: Tracy Batchelor (Estados Unidos)
Translational research for gliomas: future landscapes and emerging paradigm
Speaker: Vinay K. Puduvalli (Estados Unidos)
The role of CAR T cell therapy in neurooncology
Speaker: Andreas Hottinger (Suíça)
What we do know about non-standard of care treatments for gliomas: cannabis, antidepressants, metformin and others
Speaker: Yvonne Kew (Estados Unidos)
Bevacizumab, is there still a role for antiangiogenics in glioblastoma?
Speaker: Juan Sepulveda (Espanha)
The optimal timing of palliative care in glioma patients
Speaker: Daniel Neves Forte (SP)
How feasible is surgery in the motor area?
Speaker: Lorenzo Bello (Itália)
Discussion
Realização
Organização
agência de turismo
PATROCÍNIO PRATA
PATROCÍNIO BRONZE
APOIO
Apoio Institucional
